MPIMalaysian Pharmaceutical
Intelligence
BETALook up
The fields · the register by therapeutic area

Every therapeutic field, read the same way.

5 fields tracked closely, 32 molecules, one register. Each field described the same way — its disease burden, and how its market is structured by makers and patent status. The facts, field by field; no verdict.

Generic-open — off-patent, generics registeredNear cliff — patent expiry within ~24 monthsMulti-source — 10+ registered makersPatent-protected — patent years out
Lipid-lowering
C10 · 7 molecules tracked
Statins and a fibrate. The class is almost entirely off-patent and multi-sourced; value sits in the high-intensity statins.
38.1%
Prevalence
8,700,000
Patients
30%
Treated
RM 0.3–1.8B
Market / yr*
2
4
1
2 generic-open · 4 multi-source · 1 not yet registered
Open the field →
Diabetes
A10 · 6 molecules tracked
Biguanide, sulfonylureas, DPP-4 and SGLT2. The older agents are crowded; the SGLT2 class is the newest to reach the register in volume.
18.3%
Prevalence
3,900,000
Patients
43%
Treated
RM 0.3–2.0B
Market / yr*
1
1
4
1 generic-open · 1 near cliff · 4 multi-source
Open the field →
Hypertension
C02–C09 · 9 molecules tracked
CCBs, ACE inhibitors, ARBs and β-blockers. Every class here is off-patent and deeply multi-sourced — the most crowded field in the register.
30.3%
Prevalence
6,300,000
Patients
44%
Treated
RM 0.3–1.7B
Market / yr*
3
6
3 generic-open · 6 multi-source
Open the field →
Depression
N06A · 8 molecules tracked
SSRIs, SNRIs and an atypical. Off-patent and multi-sourced, but the most under-treated field — demand sits behind a diagnosis gap, not a supply gap.
2.3%
Prevalence
480,000
Patients
25%
Treated
RM 40–300M
Market / yr*
6
2
6 generic-open · 2 multi-source
Open the field →
Epilepsy
N03A · 2 molecules tracked
Modern antiepileptics. A smaller field — the newer agents carry most of the growth as older drugs fade.
0.78%
Prevalence
265,000
Patients
54%
Treated
RM 40–210M
Market / yr*
1
1
1 generic-open · 1 multi-source
Open the field →